The National Center for Tumor Diseases (NCT) is funding the multicenter CURE-GvHD study, led by Uniklinikum Erlangen, with €2.5 million from the Federal Ministry of Research, Technology, and Space. A CAR-T cell approach is being evaluated for patients with severe chronic graft-versus-host disease (cGvHD). Allogeneic blood stem cell transplantation, the transfer of donated stem cells…
/FAU Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
